CAS: 1146618-41-8; 1-(3-Chlorophenyl)-3-(5-(2-(Thieno[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Thiazol-2-yl)Urea Methanesulfonate
- 英文名称1-(3-Chlorophenyl)-3-(5-(2-(Thieno[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Thiazol-2-yl)Urea Methanesulfonate
- 中文名称N-(3-氯苯基)-N’-[5-[2-(噻吩并3,2-d]嘧啶-4-基氨基)乙基]-2-噻唑基]脲甲磺酸盐 (1:1)
- IUPAC名称1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea methanesulfonate
- CAS编号1146618-41-8
- MFCD编号:MFCD16621142
- FDA UNII编号:KGW32FDY3U
- 分子式:C19H19ClN6O4S3分子量:527.05
- 产品CID: 180618
- 同类组份化合物CAS1057249-41-8 (free base)1146618-41-8 (mesylate)
- 产品分类有机原料 → 氨基化合物 → 磺酸类氨基化合物
物理性质
- PSA:217.78
- LogP:5.1931
- 溶解性Soluble In DMSO (Up To At Least 25 mg/mL).
- 外观形态类白色固体
- 储存条件-20°
- 产品应用该化合物是AA,AURORA B和AURRA CKINASES(分别为IC50=9 NM,31 NM和3 NM)的强大和选择性抑制剂,对TRKA/B,FLT4,FMS,AXL,C-RAF和DDR2的打击活动较弱. 它有效抑制了各种肿瘤细胞线(IC50 =1.8-24 NM,独立于细胞A或AUROS-A或B蛋白水平.SNS314 甲基甲酸抑制SER10的HTONE H3磷酸化,导致HCT116细胞的阻断.它显示出与碳白素,宝石,五氟,黄素或SN-38相结合的抗生毒效应,并显示出与宝石,高糖税或维辛基素的协同活动.在VIVIVO, SNS-3-14 甲基丙基磺酸对HCT 116 XENGRAFTS 的HCT116 和显微的抗菌模型显示显著抗菌活性活性.
上下游产品
SNS-314 methanesulfonic acid 14H21N3O2SC14H21N3O2S合成工艺路线路线简述
- 合成目标产物 N-(3-Chlorophenyl)-N'-[5-[2-(Thieno[3,2-D]Pyrimidin-4-Ylamino)Ethyl]-2-Thiazolyl]Urea Methanesulfonate (1:1) 主要起始原料 Ethanamine, N-[(3,5-Dichlorophenyl)Methylene]-2,2-Diethoxy-
- (文献来源)合成步骤主要原料 Ethanamine, N-[(3,5-Dichlorophenyl)Methylene]-2,2-Diethoxy-
📜4-(Thieno[3,2-D]Pyrimidin-4-Ylamino)Butanal;Hydrochloride置于溴,三乙胺体系中,用 乙醇,水,溶剂黄146,乙腈 用作溶剂,化学反应 16.38H,反应生成N-(3-氯苯基)-N'-[5-[2-(噻吩并3,2-D]嘧啶-4-基氨基)乙基]-2-噻唑基]脲甲磺酸盐 (1:1)
参考文献: Aurora Kinase Inhibitors[fr] Inhibiteurs Des Aurora Kinases
标题: Aurora Kinase Inhibitors[fr] Inhibiteurs Des Aurora Kinases
海关参考信息
- 2903919090-氯苯
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Liu F, Wang G, Wang X, Che Z, Dong W, Guo X, Wang Z, Chen P, Hou D, Zhang Q, Zhang W, Pan Y, Yang D, Liu H. Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma. Oncotarget. 2017 Apr 25;8(17):27953-27965. doi: 10.18632/oncotarget.15853.
2: Quagliariello V, Armenia E, Aurilio C, Rosso F, Clemente O, de Sena G, Barbarisi M, Barbarisi A. New Treatment of Medullary and Papillary Human Thyroid Cancer: Biological Effects of Hyaluronic Acid Hydrogel Loaded With Quercetin Alone or in Combination to an Inhibitor of Aurora Kinase. J Cell Physiol. 2016 Aug;231(8):1784-95. doi: 10.1002/jcp.25283. Epub 2016 Feb 2. Review. doi: 10.1517/13543776.2014.931374. Epub 2014 Jun 26. Review. doi: 10.3390/ijms11114326.
7: Lok W, Klein RQ, Saif MW. Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs. 2010 Apr;21(4):339-50. doi: 10.1097/CAD.0b013e3283350dd1. Review. doi: 10.1007/s00280-009-1076-8. Epub 2009 Aug 1. doi: 10.1016/j.bmcl.2009.07.016. Epub 2009 Jul 9. doi: 10.1158/1535-7163.MCT-08-0754. doi: 10.1016/j.bmcl.2009.01.043. Epub 2009 Jan 19. doi: 10.1016/j.bmcl.2008.07.073. Epub 2008 Jul 24.
合成参考文献
参考文献:10.1007/s11912-008-0020-0
摘要:Warner SL, Stephens BJ, Von Hoff DD. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep. 2008 Mar;10(2):122–9. doi: 10.1007/s11912-008-0020-0.
📝 需求与反馈
尽可能描述清楚需求与问题信息
